A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Ollin Biosciences, Inc.
- Study ID
- NCT07484074
- Phase
- PHASE1
- Status
- Completed
Conditions
- Diabetic Macular Edema (DME)
- Neovascular (Wet) Age-Related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Faricimab — DRUGIntravitreal Injection
- OLN324 — DRUGIntravitreal Injection
Study Details
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
Key Dates
- Start date
- Feb 12, 2025
- Status verified
- Mar 2026
- Primary completion
- Oct 10, 2025
- Completion
- Dec 9, 2025
Study Design
- Enrollment
- 164 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: faricimab 6mg
- Experimental: OLN324 2mg
- Experimental: OLN324 4mg
Primary Outcome Measure
Adverse Events [ Time Frame: Week 12 and Week 20 ]
Locations (29)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Phoenix, AZ | Phoenix | Arizona | 85016 | - |
| Glendale, CA | Glendale | California | 91204 | - |
| Pasadena, CA | Pasadena | California | 91107 | - |
| Sacramento, CA | Sacramento | California | 95825 | - |
| Walnut Creek, CA | Walnut Creek | California | 94598 | - |
| Waterford, CT | Waterford | Connecticut | 06385 | - |
| Fort Myers, FL | Fort Myers | Florida | 33912 | - |
| Saint Petersburg, FL | St. Petersburg | Florida | 33711 | - |
| Winter Haven, FL | Winter Haven | Florida | 33880 | - |
| Oak Forest, IL | Oak Forest | Illinois | 60452 | - |
| Hagerstown, MD | Hagerstown | Maryland | 21740 | - |
| Grand Rapids, MI | Grand Rapids | Michigan | 49546 | - |
| Reno, NV | Reno | Nevada | 89502 | - |
| Wake Forest, NC | Wake Forest | North Carolina | 27587 | - |
| Tulsa, OK | Tulsa | Oklahoma | 74114 | - |
| Springfield, OR | Springfield | Oregon | 97477 | - |
| Germantown, TN | Germantown | Tennessee | 38138 | - |
| Abilene, TX | Abilene | Texas | 79606 | - |
| Arlington, TX | Arlington | Texas | 76012 | - |
| Austin, TX | Austin | Texas | 78705 | - |
| Bellaire, TX | Bellaire | Texas | 77401 | - |
| Dallas, TX | Dallas | Texas | 75231 | - |
| Katy, TX | Katy | Texas | 77494 | - |
| Plano, TX | Plano | Texas | 75075 | - |
| Round Rock, TX | Round Rock | Texas | 78681 | - |
| San Antonio, TX | San Antonio | Texas | 78240 | - |
| San Marcos, TX | San Marcos | Texas | 78666 | - |
| Schertz, TX | Schertz | Texas | 78154 | - |
| The Woodlands, TX | The Woodlands | Texas | 77384 | - |
Find similar trials in Phoenix, AZ
Related Studies
- 4D-150 in Patients With Neovascular (Wet) Age-Related Macular DegenerationPHASE1/PHASE2 · Recruiting · 4D Molecular Therapeutics · Phoenix, Arizona
- A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMDRecruiting · Skyline Therapeutics · Boston, Massachusetts
- High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous VitrectomyPHASE4 · Recruiting · Retina Consultants of Orange County · Fullerton, California
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Gilbert, Arizona